TGA to monitor pancreatic effects of gliptins

The European Medicines Agency (EMA) acted on research suggesting an increased risk of pancreatitis and pancreatic-duct metaplasia in patients with type 2 diabetes treated with gliptins and other glucagon-like peptide (GLP)-1 based therapies.

The pathological changes were seen in pancreatic samples obtained from 34 organ donors, with or without diabetes mellitus, who had died from a cause other than their diabetes.

Last month the FDA, which had previously warned of post-marketing reports of acute pancreatitis associated with the